NCT02579044

Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria

• Status: Enrolling By Invitation
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Boston Children's Hospital · Academic / Other
• Sex: All
• Age: 18 Months – 25 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I/II dose-escalation trial of everolimus in combination with lonafarnib in Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies (henceforth "progeria"). The study will be conducted at a single clinical site utilizing the Clinical and Translational Study Unit (CTSU) at Boston Children's Hospital. Lonafarnib will be administered at doses previously established in the pediatric population and in this population of progeria subjects. This study will first determine the dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD) of everolimus when administered in combination with lonafarnib. It will then determine the efficacy of everolimus when administered at its MTD in combination with lonafarnib for disease in progeria.

Conditions

• Progeria

Interventions

Type	Name	Description
DRUG	Everolimus and lonafarnib

Timeline

• Start date: 2015-12-01
• Primary completion: 2027-03-01
• Completion: 2027-03-01
• First posted: 2015-10-19
• Last updated: 2026-04-02

Locations

1 site across 1 country: United States